Description
Product Overview
Lamisil Uno is created for the treatment of foot fungus in just one application. days after application.
During this time, terbinafine fights the infection causing the fungus (mycosis) of the foot. *
* Instructions for medical use, RU No LSR-003583/07 of 11/06/2007
Description
Solution for external use, film-forming 1% transparent or slightly matte, viscous, colorless to light yellow in color, with an ethanol odor.
Product form
solution for external application
Pharmacological action
Antifungal drug for external use with a wide spectrum of antifungal activity. In small concentrations, terbinafine has a fungicidal effect against dermatophytes (Trychophyton rubrum, Trychophyton mentagrophytes, Trychophyton verrucosum, Trychophyton violaceum, Trychophyton tonsurans, Microsporum canis, Epidermophyton floccosum), mold (mainly Candida albicoricum fungi) and fungi.
Activity against yeast fungi, depending on their type, can be fungicidal or fungistatic.
Terbinafine specifically modifies the early stage of sterol biosynthesis in fungi. This leads to ergosterol deficiency and to intracellular accumulation of squalene, which causes the death of the fungal cell.
The action of terbinafine is carried out by inhibiting the squalene epoxidase enzyme located on the cell membrane of the fungus.
Squalene epoxidase is not associated with the cytochrome P450 system. Terbinafine does not affect the metabolism of hormones or other drugs.
Indications
Mycoses (dermatophytosis) of the feet (tinea pedis).
Use during pregnancy and lactation
Clinical experience with the use of Lamisil ® Uno for external use during pregnancy is very limited, the drug should be used only for strict indications.
Terbinafine is excreted in breast milk, therefore, the drug should not be prescribed to nursing mothers.
In experimental studies of teratogenic properties of terbinafine not detected. To date, no malformations have been reported with the use of Lamisil ® Uno.
Composition
1 g of solution contains:
Active ingredient:
terbinafine hydrochloride 10 mg
Excipients:
macrogol cetostearyl ether,
ethanol,
purified water,
propylene glycol,
nitrogen.
Dosage and administration
The drug is used externally, once.
For adults and adolescents over the age of 15, the Lamisil ® Uno film-forming solution is applied 1 time to both feet, even if a fungal infection is observed on only one foot. This ensures the destruction of fungi (dermatophytes), which can be located in areas of the foot where lesions are not visually noticeable.
Wash and dry your feet and hands before applying the drug. First, one foot is processed, then another. Starting the procedure on the interdigital areas, a thin layer should be applied evenly between the toes and around the entire surface of the fingers, as well as on the sole and lateral parts of the foot up to a height of 1.5 cm.
Use a sufficient amount of the preparation to cover the required skin surface, usually 1 / 2 tubes for processing each foot.
The other foot should be processed in the same way, even if the skin on it looks healthy. Dry the solution for 1-2 minutes until a film is formed. After finishing the treatment, feet should be washed in hands.
Do not reapply the product on treated skin.
Lamisil ® Uno should not be rubbed into the skin.
Side effects
Side effects are extremely rare, mild and are short-lived.
Systemic reactions: very rare (<1/10 000) - allergic reactions (rash, redness, bullous dermatitis and urticaria). Local reactions: rarely (> 1/1000, <1/100) - dryness, skin irritation or burning sensation in the treated area of the skin. Drug Interaction The current drug interaction of Lamizil ® Uno is unknown. Overdose No cases of overdose have been reported. An overdose is unlikely, since the drug is available in an amount necessary for single use and intended for external use. Symptoms: headache, nausea, epigastric pain, and dizziness may occur with accidental ingestion. Treatment: Activated Carbon Assignment, if necessary, conduct symptomatic therapy in a hospital setting. Storage conditions At a temperature below 30 ° C Shelf suitability 3 Year Deystvuyuschee substances Terbinafine pharmacy leave terms without a prescription Dosage Dosage form pma solution for external use
